Oxford Biomedica

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. Our technology platforms include a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, we have a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb and Immune Design Corp.
Type
Public
HQ
Oxford, GB
Founded
1995
Size (employees)
231 (est)+73%
Oxford Biomedica was founded in 1995 and is headquartered in Oxford, GB

Oxford Biomedica Office Locations

Oxford Biomedica has an office in Oxford
Oxford, GB (HQ)
Transport Way

Oxford Biomedica Data and Metrics

Oxford Biomedica Financial Metrics

Oxford Biomedica's revenue was reported to be £27.8 m in FY, 2016 which is a 75% increase from the previous period.
GBP

Revenue (FY, 2016)

27.8 m

Revenue growth (FY, 2015 - FY, 2016), %

75%

Gross profit (FY, 2016)

15.9 m

Gross profit margin (FY, 2016), %

57%

Net income (FY, 2016)

(16.6 m)

Market capitalization (19-Jul-2017)

280.6 m

Closing share price (19-Jul-2017)

0.1

Cash (31-Dec-2016)

15.3 m
Oxford Biomedica's current market capitalization is £280.6 m.
GBPFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

5.4 m13.6 m15.9 m27.8 m

Revenue growth, %

153%17%75%

Cost of goods sold

1.1 m4.4 m5.8 m11.8 m

Gross profit

4.2 m9.2 m10.1 m15.9 m

Gross profit Margin, %

79%68%63%57%

Operating expense total

17.1 m19.8 m24.2 m27.3 m

Pre tax profit

(12.8 m)(10.8 m)(17 m)(20.3 m)

Net Income

(11.1 m)(8.7 m)(13 m)(16.6 m)
GBPFY, 2013FY, 2014FY, 2015FY, 2016

Cash

2.2 m14.2 m9.4 m15.3 m

Accounts Receivable

1.7 m4 m8.5 m4.9 m

Current Assets

6.9 m22.8 m25.7 m27.4 m

PP&E

4.1 m8.9 m24.4 m28.2 m

Goodwill

2.6 m2.1 m1.7 m1.3 m

Total Assets

13.6 m33.8 m51.9 m56.9 m

Accounts Payable

1.2 m2.8 m3.6 m1.6 m

Current Liabilities

4.2 m9.2 m13.2 m9.3 m

Total Liabilities

4.7 m10.8 m41 m44.3 m

Retained Earnings

(11.1 m)(8.7 m)(13 m)(16.6 m)

Total Equity

8.9 m23 m10.9 m12.6 m

Financial Leverage

1.5 x1.5 x4.8 x4.5 x
GBPFY, 2013FY, 2014FY, 2015FY, 2016

Cash From Operating Activities

(11 m)(6 m)(13.1 m)(5.1 m)

Cash From Financing Activities

23.6 m25 m17.5 m

Income Taxes Paid

1.7 m2.1 m4 m3.7 m
Y, 2016

Financial Leverage

4.5 x

Oxford Biomedica Operating Metrics

Oxford Biomedica's Clinical Programs was reported to be 114 in FY, 2015
FY, 2015

Patents Issued

100

Clinical Programs

114

Oxford Biomedica Market Value History

Oxford Biomedica Online and Social Media Presence

Oxford Biomedica News and Updates

Oxford Biomedica Company Life and Culture

You may also be interested in